atazanavir sulfate has been researched along with Adult Fanconi Syndrome in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Bani-Sadr, F; Berger, JL; Brunet, A; Favarel-Garrigues, M; Hentzien, M | 1 |
Bonnet, F; Cazanave, C; Dabis, F; Dauchy, FA; de La Faille, R; Dupon, M; Greib, C; Lawson-Ayayi, S; Mehsen, N; Miremont-Salamé, G; Rigothier, C | 1 |
2 other study(ies) available for atazanavir sulfate and Adult Fanconi Syndrome
Article | Year |
---|---|
Life-threatening rhabdomyolysis and Fanconi syndrome related to tenofovir disoproxil fumarate administration in an HIV-infected patient.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Fanconi Syndrome; Fluid Therapy; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Rhabdomyolysis; Tenofovir | 2020 |
Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cross-Sectional Studies; Fanconi Syndrome; Female; France; HIV Infections; HIV-1; Humans; Kidney Tubules, Proximal; Logistic Models; Male; Middle Aged; Odds Ratio; Oligopeptides; Organophosphonates; Prevalence; Pyridines; Risk Assessment; Risk Factors; Tenofovir; Time Factors | 2011 |